Login to Your Account



Flexion flexes FX006 time line, aims to start pivotal phase III in 4Q

By Marie Powers
Staff Writer

Thursday, September 4, 2014
Shares of Flexion Therapeutics Inc. got a boost Thursday morning after the company disclosed plans to launch a pivotal phase III trial of lead candidate FX006 by year-end and to complete the study by the end of 2015 – a year earlier than initially planned.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription